Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

f Ambit's drug development programs, including the submission of regulatory filings and planned discussions with regulatory bodies, plans regarding future clinical trials of quizartinib and Ambit's other drug candidates, the progress and expected timing of clinical trials, the presentation of data from clinical trials, the clinical benefits to be derived from quizartinib and Ambit's other drug candidates, the regulatory approval path for quizartinib, the strength of Ambit's balance sheet and adequacy of cash on hand, and Ambit's financial guidance.. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as  "plans," "expects," "anticipates," "hopes", "may," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

  Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Statements of Operations(unaudited, in thou
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... VANCOUVER, British Columbia If the increased use of biomass ... attention needs to be paid to logistics how, for ... as well as the development of better ways of preparing ... tackled by Michigan State University,s Bruce Dale, a professor of ...
... Three University of New Hampshire faculty members will ... scale, and speedier computer planning, thanks to prestigious Faculty ... Foundation. The grants, totaling nearly $1.3 million over five ... Wosnik of the mechanical engineering department and Wheeler Ruml ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the Citi ... The live presentation takes place on Wednesday, ... a.m. Pacific Time.  The presentation will be webcast and ...
Cached Biology Technology:Improving logistics of biofuel raw materials 2NSF CAREER grants support ocean energy, microforming, computer planning 2
(Date:4/17/2014)... is available in German . ... recognise objects; they also provide us with a continuous stream ... around, fall or sit still in a car the ... on our retinas. Seemingly without effort, our brain calculates self-motion ... stable position and a steady gaze during our own movements. ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
Breaking Biology News(10 mins):How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... stimulating the frontal cortex in adults, researchers have shown that ... people's actions. , It has been known for over ... the left frontal cortex, he or she often suffers difficulties ... language impairments, it has been difficult for researchers to test ...
... infections resistant to antibiotics, previously only associated with ... are now widespread in the community and coming ... University School of Medicine and Grady Memorial Hospital, ... Internal Medicine, reports on a dramatic rise in ...
... 68,000 infants published in this week's New England Journal ... can safely prevent 98 percent of severe cases of ... hospital visits and 500,000 pediatric deaths each year worldwide. ... trials ever conducted worldwide, research championed by an Eastern ...
Cached Biology News:Study indicates dramatic rise in antibiotic-resistant community-acquired staph infections 2Study indicates dramatic rise in antibiotic-resistant community-acquired staph infections 3New vaccine for condition that kills 500,000 children a year 2New vaccine for condition that kills 500,000 children a year 3
... movements in a Morris Water Maze. Tracks ... predefined sequence of trials.The Spatial Behavior line is ... video camera, frame grabber, and feature extraction software ... and up to 6 moving animals. Software ...
... directed toward examining a novel object in the ... instruments all built around a video camera, frame ... track two fields at once and up to ... positions and records them, but also allows video ...
... Reagent Grade C 19 H 9 Br ... PRODUCT SPECIFICATIONS Form: Powder Clarity of Solution: ... 3.0 - Yellow pH 4.6 - ... in agarose and acrylamide gel electrophoresis. Used ...
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
Biology Products: